Drug Developers Fund Rare Disease Registries

Many such registries have been created by advocacy groups, government agencies, or companies over the years, but they are “becoming a very common step for companies developing therapeutics,” said Vanessa Rangel Miller, vice president of genetic services at PatientCrossroads, a registry management company. And increasingly these registries rely not on medical charts but on patients’ own reports to get a better sense of how their diseases and treatments affect them day to day.

Read Full Article »
Comment
Show commentsHide Comments

Related Articles